Drug Trial Radar · NCT05958121
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 9, 2023
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Immatics Biotechnologies GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jul 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: * To determine the maximum tolerated doses and/or recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia) * To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I/II) * To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) Secondary objectives: * To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I) * To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) * To describe the PK of IMA402 as monotherapy and in combination (Phase I/II)
Conditions
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer
Interventions
IMA402Drug
IV infusions
IMA402 and checkpoint inhibitorDrug
IMA402 IV infusions and checkpoint inhibitor
IMA402 and chemotherapyDrug
IMA402 IV infusions and chemotherapy
IMA402 and IMA401Drug
IMA402 and IMA401 IV infusions
IMA402 and monoclonal antibodyDrug
IMA402 IV infusions and monoclonal antibody
IMA402 and chemotherapy +/- monoclonal antibodyDrug
IMA402 IV infusions and chemotherapy +/- monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Number of patients with dose limiting toxicities (DLTs)Time frame: 24 months
- Phase I/II: Number of patients with treatment-emergent adverse events (TEAEs)Time frame: 40 months
- Phase I/II: Number of patients with serious TEAEsTime frame: 40 months
- Phase I/II: Frequency of dose interruptions and reductions, permanent discontinuationsTime frame: 40 months
- Phase I/II: Duration of dose interruptions and reductions, permanent discontinuationsTime frame: 40 months
- Phase II: Overall response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) locally assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)Time frame: 40 months
Locations
29 sites in 2 countries. Site status is shown where the registry gives one.
Universitaetsklinikum Heidelberg AöR
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Thoraxklinik Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Mannheim GmbH
Mannheim, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Tuebingen AöR
Tübingen, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Ulm AöR
Ulm, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Erlangen AöR
Erlangen, Bavaria, Germany · Recruiting
Klinikum Nürnberg
Nuremberg, Bavaria, Germany · Completed
Universitaetsklinikum Regensburg
Regensburg, Bavaria, Germany · Recruiting
Universitaetsklinikum Wuerzburg AöR
Würzburg, Bavaria, Germany · Recruiting
Goethe University Frankfurt
Frankfurt am Main, Hesse, Germany · Recruiting
Justus-Liebig-Universitaet Giessen
Giessen, Hesse, Germany · Recruiting
Philipps-Universitaet Marburg
Marburg, Hesse, Germany · Recruiting
Sana Klinikum Offenbach GmbH
Offenbach, Hesse, Germany · Not yet recruiting
Elbe Kliniken Stade- Buxtehude Elbe Klinikum Buxtehude gGmbH
Buxtehude, Lower Saxony, Germany · Recruiting
Universitaetsmedizin Goettingen
Göttingen, Lower Saxony, Germany · Not yet recruiting
Universitaetsklinikum Bonn AöR
Bonn, North Rhine-Westphalia, Germany · Recruiting
Marien Hospital Duesseldorf GmbH
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
KEM I Evang. Kliniken Essen-Mitte gGmbH
Essen, North Rhine-Westphalia, Germany · Recruiting
Universitaetsklinikum Essen AöR
Essen, North Rhine-Westphalia, Germany · Recruiting
Johannes Wesling Klinikum Minden
Minden, North Rhine-Westphalia, Germany · Recruiting
Universitaet Muenster
Münster, North Rhine-Westphalia, Germany · Not yet recruiting
Klinikum Chemnitz gGmbH
Chemnitz, Saxony, Germany · Completed
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Dresden, Saxony, Germany · Recruiting
University Of Leipzig
Leipzig, Saxony, Germany · Recruiting
Universitaetsklinikum Magdeburg AöR
Magdeburg, Saxony-Anhalt, Germany · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands · Recruiting
Antoni von Leeuwenhoek- Netherlands Cancer Institute
Amsterdam, North Holland, Netherlands · Recruiting
Leiden Universitair Medisch Centrum
Leiden, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.